Biomedical Engineering Reference
In-Depth Information
226. Zhang, X., Xie, Y., Jin, Y., Hou, X., Ye, L., Lou, J., 2004, “The effect of RMP-7
and its derivative on transporting Evans blue liposomes into the brain,” Drug
Deliv., 11, pp. 301-309.
227. Karyekar, C.S., Fasano, A., Raje, S., Lu, R., Dowling, T.C., Eddington, N.D.,
2003, “Zonula occludens toxin increases the permeability of molecular weight
markers and chemotherapeutic agents across the bovine brain microvessel
endothelial cells,” J. Pharm. Sci., 92, pp. 414-423.
228. Dallasta, L.M., Pisarov, L.M., Esplen, L.A., Werley, J.V., Moses, A.V., et al.,
1999, “Blood-brain barrier tight junction disruption in human immu-
nodeficiency virus-1 encephalitis,” Am. J. Pathol., 155, pp. 1915-1927.
229. Hynynen, K., McDannold,N., Vykhodtseva, N., Jolesz, F.A., 2001,
“Noninvasive MR imaging-guided focal opening of the blood-brain barrier in
rabbits,” Radiology, 220, pp. 640-646.
230. McDannold, N., Vykhodtseva, N., Hynynen, K., 2004, “Use of ultrasound
pulses combined with definity for targeted blood-brain barrier disruption: a
feasibility study,” Ultrasound Med. Biol., 33, pp. 584-590.
231. Sheikov, N. McDannold, N. Vykhodtseva, N., Jolesz, F., Hynynen, K.,
2004, “Cellular mechanisms of the blood-brain barrier opening induced
by ultrasound in presence of microbubbles,” Ultrasound Med. Biol., 30,
pp. 979-989.
232. Treat, L.H., McDannold, N. Vykhodtseva, N., Zhang, Y., Tam, K. Hynynen,
K., 2007, “ Targeted delivery of doxorubicin to the rat brain at therapeutic
levels using MRI-guided focused ultrasound,” Int. J. Cancer, 121, pp. 901-
907.
233. Maclean, A.G., Belenchia, G.E., Bieniemy, D.N., Moroney-Rasmussen, T.A.,
Lackner, A.A., 2005, “Simian immunodeficiency virus disrupts extended
lengths of the blood-brain barrier,” J. Med. Primatol., 34, pp. 237-242.
234. Pandit, J.K., Singh, S., Muthu, M.S., 2006, “Controlled release formulations in
neurology practice,” Ann. Indian Acad. Neurol., 9, pp. 207-216.
235. Thakur, A., Gahane, A., Bhadoriya, S.S., Jain, S.K., Jain, R., Mishra, H., 2011,
“Major hurdles for brain tumor therapy and the ways to overcome them: A
review,” J. Pharmacy Res., 4, pp. 1315-1318.
236. Bobo, R.H., Douglas, W., Akbasak, A., Morrison, P.F., Dedrick, R.L., Oldfield,
E.H., 1994, “Convection-enhanced delivery of macromolecules in the brain,”
Proc. Natl. Acad. Sci. U.S.A., 91, pp. 2076-2080.
237. Attenello, F.J., Mukherjee, D., Datoo, G., McGirt, M.J., Bohan, et al., 2008,
“Use of Gliadel (BCNU) wafer in the surgical treatment of malignant
glioma: a 10-year institutional experience,” Ann. Surg. Oncol., 15, pp. 2887-
2893.
238. Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Bick, N.A., 1995,
“Placebo controlled trial of safety and efficacy of intraoperative controlled
delivery by biodegradable polymers for recurrent gliomas,” Lancet, 345,
pp. 1008-1012.
239. Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., et al., 2003,
“A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU)
wafers (Gliadel wafers) in patients with primary malignant gliomas,” Neuro.-
Oncol., 5, pp. 79-88.
